Literature DB >> 8216374

Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.

G Los1, M J van Vugt, L den Engelse, H M Pinedo.   

Abstract

Increased levels of cisplatin (cDDP)- and carboplatin (CBDCA)-DNA adducts were detected in cDDP (10 microM)- and CBDCA (6 mM)-treated CC531 cells when the temperature was raised from 37 degrees to 43 degrees. In the case of cDDP, increased DNA adduct formation was already detectable at 38.5 degrees; additional temperature steps led to further increases in DNA modification. Increased CBDCA-DNA adduct formation was observed only at temperatures higher than 40 degrees. In vitro studies on the interaction of CDDP and CBDCA with isolated salmon sperm DNA, however, demonstrated no significant differences in the DNA binding rate between 37 degrees and 43 degrees for cDDP and a minor effect for CBDCA only at 43 degrees, almost totally excluding a direct temperature effect on DNA platination in this temperature range. Furthermore, neither the stability of the formed platinum-DNA adducts nor the rate of adduct loss in CC531 cells was changed at higher temperatures. The observed difference in cellular adduct formation, however, could be related to increased uptake of cDDP and CBDCA into CC531 cells at higher temperatures. In the case of cDDP, a temperature shift from 37 degrees to 38.5 degrees resulted in a significantly higher intracellular platinum concentration (0.03 +/- 0.01 vs 0.071 +/- 0.021 micrograms platinum/10(6) cells, respectively); for CBDCA, temperatures > or = 41.5 degrees were needed to increase the platinum concentration significantly above 37 degree values (0.3 +/- 0.1 vs 0.6 +/- 0.1 micrograms platinum/10(6) cells, respectively). In addition, the increase in DNA adduct formation of cDDP and CBDCA at elevated temperatures was comparable with the increase in cDDP-DNA adducts after a cDDP concentration escalation at 37 degrees, indicating a concentration-dependent increase in cDDP-DNA adducts. It seems that heat affects primarily the cellular uptake of cDDP and CBDCA and not their covalent binding to DNA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216374     DOI: 10.1016/0006-2952(93)90472-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.

Authors:  Renee A Cowan; Roisin E O'Cearbhaill; Oliver Zivanovic; Dennis S Chi
Journal:  Int J Hyperthermia       Date:  2017-08       Impact factor: 3.914

2.  Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.

Authors:  Itaru Sato; Masanari Umemura; Kenji Mitsudo; Mitomu Kioi; Hideyuki Nakashima; Toshinori Iwai; Xianfeng Feng; Kayoko Oda; Akiyoshi Miyajima; Ayako Makino; Maki Iwai; Takayuki Fujita; Utako Yokoyama; Satoshi Okumura; Motohiko Sato; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2014-03-12       Impact factor: 2.781

3.  Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.

Authors:  R C Rietbroek; P J van de Vaart; J Haveman; F A Blommaert; A Geerdink; P J Bakker; C H Veenhof
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 4.  How do we perform hyperthermic intraperitoneal chemotherapy in ovarian cancer? -a narrative review.

Authors:  Hyeong In Ha; Myong Cheol Lim
Journal:  Gland Surg       Date:  2021-03

Review 5.  Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy.

Authors:  Aditi Bhatt; Olivier Glehen
Journal:  Visc Med       Date:  2022-01-10

6.  Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.

Authors:  Lea A Moukarzel; Lorenzo Ferrando; Higinio Dopeso; Anthe Stylianou; Thais Basili; Fresia Pareja; Arnaud Da Cruz Paula; Gabriele Zoppoli; Nadeem R Abu-Rustum; Jorge S Reis-Filho; Kara Long Roche; William P Tew; Dennis S Chi; Yukio Sonoda; Dmitriy Zamarin; Carol Aghajanian; Roisin E O'Cearbhaill; Oliver Zivanovic; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2022-03-12       Impact factor: 5.304

7.  Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Authors:  Tejinder Kaur; Prerna Makkar; Kulbir Randhawa; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2012-09-09       Impact factor: 2.289

8.  PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.

Authors:  Mustafa Raoof; Gautam Malhotra; Adrian Kohut; Michael O'Leary; Paul Frankel; Thuy Tran; Marwan Fakih; Joseph Chao; Dean Lim; Yanghee Woo; Isaac B Paz; Michael Lew; Mihaela C Cristea; Lorna Rodriguez-Rodriguez; Yuman Fong; Andrew Blakely; Richard Whelan; Marc A Reymond; Amit Merchea; Thanh H Dellinger
Journal:  Ann Surg Oncol       Date:  2021-08-13       Impact factor: 5.344

9.  Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.

Authors:  Oliver Zivanovic; Dennis S Chi; Qin Zhou; Alexia Iasonos; Jason A Konner; Vicky Makker; Rachel N Grisham; Amy K Brown; Stacy Nerenstone; John P Diaz; Eric D Schroeder; Carrie L Langstraat; Viktoriya Paroder; Yulia Lakhman; Krysten Soldan; Katy Su; Ginger J Gardner; Vaagn Andikyan; Jianxia Guo; Elizabeth L Jewell; Kara Long Roche; Tiffany Troso-Sandoval; Stuart M Lichtman; Lea A Moukarzel; Kimberly Dessources; Nadeem R Abu-Rustum; Carol Aghajanian; William P Tew; Jan Beumer; Yukio Sonoda; Roisin E O'Cearbhaill
Journal:  J Clin Oncol       Date:  2021-05-21       Impact factor: 50.717

10.  Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy.

Authors:  Tristan D Yan; Oswald A Stuart; Dal Yoo; Paul H Sugarbaker
Journal:  J Transl Med       Date:  2006-04-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.